CHICAGO, Oct. 21 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS) today announced that it has scheduled the following scientific and investor conference presentations and third quarter 2008 earnings conference call.
-- 48th Annual ICAAC/IDSA Annual Meeting in Washington D.C. from October 25 through October 28. Advanced Life Sciences will present clinical and microbiology data in posters and an oral presentation pertaining to its lead respiratory antibiotic cethromycin. The Company will also sponsor a "Meet the Experts" series focused on respiratory tract pathogens and bacterial resistance led by infectious disease physicians Dr. Thomas File and Dr. Donald Low during the conference.
-- Rodman & Renshaw Annual Global Investment Conference in New York City on Wednesday, November 12, 2008 at 2:50PM ET.
-- Lazard Capital Markets 5th Annual Healthcare Conference in New York City on Tuesday, November 18, 2008 at 1:10PM ET.
A live webcast will be available for each of the investor conferences, and may be accessed under "Event Calendar" on the Investors section of Advanced Life Sciences website at http://www.advancedlifesciences.com.
-- Third Quarter Earnings Conference Call to be webcast live over the internet on November 6th at 10:00AM ET. To access the webcast, visit the Investor Relations section of the Advanced Life Sciences corporate website at http://www.advancedlifesciences.com. Alternatively, investors may participate in the conference call by dialing 888-680-0893 (domestic) or 617-213-4859 (international). The passcode for the conference call is 80103777. A replay of the conference call will be available until November 13, 2008. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 96626416. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PN3D7M9E4. Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel NDA-stage once-a-day oral antibiotic for the treatment of respiratory tract infections including community acquired pneumonia. For more information, please visit us on the web at http://www.advancedlifesciences.com.
Any statements contained in this press release that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. These risks and
uncertainties include, among others, those relating to technology and
product development, market acceptance, government regulation and
regulatory approval processes, intellectual property rights and litigation,
dependence on collaborative relationships, ability to obtain financing,
competitive products, industry trends and other risks identified in
Advanced Life Sciences' filings with the Securities and Exchange
Commission. Advanced Life Sciences undertakes no obligation to update or
alter these forward-looking statements as a result of new information,
future events or otherwise.
Company Contact: Joe Camp 630-754-4352
Media Contact: Melanie Nimrodi, Financial Relations Board, 312-546-3508
Investors Contact: Kathy Price, Financial Relations Board, 213-486-6547
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved